GLP-1 medications have become popular for weight loss, and for good reason—they can help regulate appetite and support weight ...

as prior studies have reported GLP-1 receptor agonist discontinuation rates of up to 81%, Emanuel's group wrote. They added that the links between weight loss and discontinuation and between ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...

glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published online January 7 in the Annals of Internal Medicine. Areesha Moiz ...

Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” A Type 2 diabetes medication that can also aid in weight loss ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to scale down their dosing if, for example, they experienced side effects like ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...